BioWorld Asia

Sep. 19, 2007

NeuroSearch Shares Boosted By Tesofensine Obesity Data

Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International) Read More

Ganymed Adds To Series C; Closes 37.2M Financing Round

No Abstract Read More

Gene Expression Levels Vary At Higher Levels Than Thought

Oxford BioMedica Using Sanofi Deal As Catalyst For Growth

European Industry Seeks Wider Links In Orphan Drug Programs

Other News To Note

Renovo Reports Positive Data From Phase IIb Trial Of Juvista

Mutabilis, Oroxcell Collaborate On Preclinical Antibiotic Agent

EU Commissioner Defends Rule Banning GM-Free Zones

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...